Clinical trials: Depressive Disorders
- Condition Depressive Disorders
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Bipolar Depression
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as…
- Trial name
- NCT06372964
- Testing
- Lumateperone
- Where
- 68 sites in United States, Colombia and 2 more
- Volunteers
- 384 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Autism
Pediatric Open-Label Extension Study
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have…
- Conditions
- Schizophrenia, Autism, Bipolar Depression
- Trial name
- NCT01914393
- Testing
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed
- Where
- 88 sites in United States, Bulgaria and 13 more
- Volunteers
- 702 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
This study is a retrospective database study in Japan to evaluate the relative risk of serious intracranial hemorrhage requiring hospitalization between Vortioxetine tablet treatment and selective serotonin reuptake inhibitor…
- Trial name
- NCT05932407
- Testing
- Vortioxetine Tablet, SSRI
- Where
- Japan
- Volunteers
- 147,777 people
- Sponsor
- Takeda
Anxiety, Depression in Adolescence
Co-designing Adaptations of a Digital Mental Health Intervention (Wysa) for Adolescent Girls With Anxiety or Depression in Rural India
The goal of this study is to culturally and contextually adapt Wysa, an evidence-based AI-powered digital mental health intervention (DMHI), for adolescent girls (ages 13-18) with symptoms of anxiety and/or depression in rural…
- Conditions
- Anxiety, Depression in Adolescence, Anxiety Disorder of Adolescence
- Trial name
- NCT07595029
- Testing
- Digital psychosocial tool
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Wysa
Depression
Vortioxetine to Prevent Return of Symptoms in Children With Depression
The purpose of this study is to find out if vortioxetine is better than placebo (sugar pills) in preventing depression in children who improved when treated with vortioxetine.
- Trial name
- NCT05014919
- Testing
- Vortioxetine
- Where
- 17 sites in United States, Colombia and 5 more
- Volunteers
- 35 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).
- Trial name
- NCT01371721
- Testing
- DVS SR
- Where
- 35 sites in United States, Mexico
- Volunteers
- 269 people
- Sponsor
- Pfizer
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- NeuroQore Inc.
Depressive Symptoms, Depression
Self-guided Treatment for Adolescents Navigating Depression
The goal of this study is to test whether an investigational mobile app can be a helpful treatment option for adolescents with symptoms of depression.
- Conditions
- Depressive Symptoms, Depression, Depressive Disorder, Depressive Episode
- Trial name
- NCT05462652
- Testing
- Active Intervention
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Limbix Health, Inc.
Bipolar Disorders, Mood Disorders
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.
- Conditions
- Bipolar Disorders, Mood Disorders, Affective Disorders, Psychotic
- Trial name
- NCT00240721
- Testing
- topiramate
- Volunteers
- 363 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Suicide Ideation, Suicidal Intention
Classification and Assessment of Mental Health Performance Using Schematics
This is an open enrollment study to collect data for the optimization of smartphone-based algorithms for the early detection of mental health and suicidal risk in a student population.
- Conditions
- Suicide Ideation, Suicidal Intention, Suicide and Depression
- Trial name
- CAMPUS (NCT04275908)
- Testing
- MHSAFE app
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Clarigent Health
Depression / Major Depressive Disorder, Anxiety
Activating Voice Journaling for Mental Health With Voice Biomarkers
This retrospective observational study evaluated the relationship between voice characteristics and self-reported mental health symptoms using longitudinal data collected through the Kintsugi Voice Journaling app.
- Trial name
- NCT07789808
- Where
- United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Diabetes, Hypertension
Quality IQ Patient Simulation Physician Practice Measurement and Engagement
This study will test the quality of physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and feedback.
- Conditions
- Diabetes, Hypertension, Depression, Osteoarthritis
- Trial name
- Q-IQ (NCT03800901)
- Testing
- Continuing Medical Education, Quality IQ Patient Simulations
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Mood, Depression Disorders
Technology Exposure and Child Health: Wellness Impact and Social Effects: An Observational Product Registry Study
The goal of this study is to understand how children's mobile device usage (smartphones or tablets), including social media use and online games, are related to their mental wellness and mental health, as well as some aspects of…
- Conditions
- Mood, Depression Disorders, Anxiety Disorders, Sleep
- Trial name
- TECHWISE (NCT06664944)
- Where
- United States
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- Aura
Depressive Symptoms, Anxiety Disorders and Symptoms
Evaluating a Virtual Mentoring Program Plus Mental Health Videos for Teens
This clinical trial evaluates Appa Health, a mental health smartphone and computer app for teenagers. Appa is built from two components.
- Trial name
- NCT06138730
- Testing
- Appa Complete, Appa Lite
- Where
- United States
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Appa Health
Suicide, Mental Health Disorder
Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT06665620
- Testing
- ViraBrite nudges
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ksana Health
Depressive Disorder, Major
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition)…
- Trial name
- NCT02709746
- Testing
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day
- Where
- 124 sites in United States, Bulgaria and 17 more
- Volunteers
- 784 people
- Sponsor
- H. Lundbeck A/S
Depression, Postpartum, Postpartum Depression (PPD)
Brexanolone Lifting Outcomes Of Moms
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
- Trial name
- BLOOM (NCT07822321)
- Testing
- LPCN 1154A
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Lipocine Inc.
Parkinson Disease
The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease
Documentation of the effect of SIFROL® on tremor and depression as well as its tolerability in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions
- Trial name
- NCT02231294
- Testing
- Sifrol®
- Volunteers
- 1,464 people
- Sponsor
- Boehringer Ingelheim
Bipolar Disorder
Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents
A clinical study to determine the safety and effectiveness of risperidone compared with placebo in the treatment of bipolar disorder (manic or mixed type) in children and adolescents aged 10 to 17 years.
- Trial name
- NCT00076115
- Testing
- Risperidone
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Depression
Pediatric Bipolar Depression
The purpose of this study is to determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUEL® XR) 150 to 300 mg/day taken by itself is effective and safe in treating children or adolescents aged 10 to 17 with…
- Trial name
- NCT00811473
- Testing
- Quetiapine XR
- Where
- 48 sites in United States, Colombia and 5 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca